Study on the Safety and Effectiveness of Guanfacine Hydrochloride and Atomoxetine Hydrochloride for Children and Adolescents with ADHD Aged 6 to 17 Years

3 1 1

What is this study about?

This clinical trial is focused on studying the safety and effectiveness of a medication called Guanfacine Hydrochloride in children and adolescents aged 6 to 17 years who have been diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD is a condition that affects attention, self-control, and the ability to sit still. The study is designed to help understand how well Guanfacine Hydrochloride works and how safe it is for long-term use in young people who cannot use stimulant medications due to various reasons such as intolerance or ineffectiveness.

The trial will compare Guanfacine Hydrochloride with another medication called Atomoxetine Hydrochloride, which is also used to treat ADHD. Participants will be randomly assigned to receive either Guanfacine Hydrochloride, Atomoxetine Hydrochloride, or a placebo. The study will begin with a phase where the best dose for each participant is determined, followed by a period where the medication is taken regularly. The trial will last for a total of 12 months, during which the participants’ attention and reaction times will be monitored using a computer-based test called the Cambridge Automated Neuropsychological Test Battery (CANTAB).

The main goal of the study is to evaluate the long-term safety of Guanfacine Hydrochloride and its effects on attention and psychomotor speed, which refers to the coordination between thinking and physical movement. The study will also look at other health indicators such as weight, height, and vital signs like blood pressure and heart rate. This research aims to provide valuable information on the use of Guanfacine Hydrochloride for managing ADHD in children and adolescents.

1 joining the study

Upon joining the study, the participant will be informed about the trial’s purpose and procedures. Consent from a parent or legally authorized representative is required, along with the participant’s assent if applicable.

2 initial assessment

An initial assessment will be conducted to confirm eligibility. This includes checking intellectual functioning, ability to swallow tablets, and ensuring blood pressure is within the required range.

3 randomized treatment phase

Participants will be randomly assigned to receive either guanfacine hydrochloride or atomoxetine hydrochloride. The medication will be taken orally once daily. The dosage will be optimized based on individual response and tolerance.

4 dose optimization

During this phase, the dosage of the medication will be adjusted to find the most effective and tolerable dose for each participant. This process ensures the best possible outcome for managing symptoms.

5 double-blind evaluation

In this part of the study, neither the participants nor the researchers will know which medication is being administered. This helps to ensure unbiased results when assessing the medication’s effectiveness and safety.

6 open-label evaluation

Following the double-blind phase, all participants will receive guanfacine hydrochloride in an open-label manner, meaning both participants and researchers will know the medication being taken. This phase allows for further assessment of the medication’s long-term safety and efficacy.

7 safety and efficacy assessments

Throughout the study, regular assessments will be conducted to monitor safety and efficacy. This includes measuring reaction time, attention, and other cognitive functions using specific tests. Vital signs, weight, and other health indicators will also be monitored.

8 completion of the study

Upon completing the study, participants will undergo a final assessment to evaluate the overall impact of the treatment. This includes a review of any changes in symptoms and any side effects experienced during the trial.

Who Can Join the Study?

The participant must be a boy or girl aged 6 to 17 years old.
The participant should be able to think and understand at a level appropriate for their age, as judged by the study doctor.
The participant must be able to swallow whole tablets.
If the participant is a girl who can have children, she must have a negative pregnancy test before starting the study and agree to use birth control if required by the study rules. This applies to girls aged 9 years or older, or younger if they have started menstruating.
The participant’s blood pressure must be within the normal range for their age, sex, and height when lying down and standing up.
The participant must have a main diagnosis of ADHD according to a detailed psychiatric evaluation.
The participant must have tried stimulant medications for ADHD that were not suitable, not tolerated, or did not work, as determined by the study doctor.
The participant must have a certain score on the ADHD Rating Scale, which measures the severity of ADHD symptoms.
The participant must have a certain score on the Clinical Global Impressions-Severity (CGI-S) scale, which measures the severity of the participant’s condition.
The participant’s parent or legal guardian must sign a consent form agreeing to the participant’s involvement in the study. The participant must also agree to take part in the study and understand what it involves.
The participant and their parent or guardian must be willing and able to follow all the study requirements, including taking the study medication each morning.

Who Cannot Join the Study?

Patients who have a medical condition other than ADHD that might interfere with the study.
Patients who are currently taking medications that could affect the study results.
Patients who have a history of severe allergies or reactions to medications.
Patients who have a history of drug or alcohol abuse.
Patients who have a serious mental health condition, such as severe depression or anxiety.
Patients who are pregnant or breastfeeding.
Patients who have participated in another clinical trial within the last 30 days.
Patients who have a family history of certain heart conditions.
Patients who have a history of seizures or epilepsy.
Patients who have a significant medical condition that the study doctor believes would make participation unsafe.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Katholieke Universiteit te Leuven	Leuven	Belgium
Hospital Universitario De Navarra	Pamplona	Spain

Other Sites

Site Name	City	Country
Medical Center – University Of Freiburg	Freiburg Im Breisgau	Germany
Central Institute of Mental Health	Mannheim	Germany
Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur	Namur	Belgium
Hospital Universitario Infanta Leonor	Madrid	Spain
EB FlevoResearch B.V.	Almere	The Netherlands
Vaestra Goetalandsregionen	Gothenburg	Sweden
Poht Teyax Huhhwgzx Udvrgupgjbnj	Sabadell	Spain
Usjqqgszrh Hoxnkvid Chaihoc Agw	Cologne	Germany
Riaxiuqsmpsozmqdvvogdj Mxoxq	Mainz	Germany

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	18.09.2019
Germany	Not recruiting	18.09.2019
Spain	Not recruiting	18.09.2019
Sweden	Not recruiting	18.09.2019
The Netherlands	Not recruiting	18.09.2019

Trial locations

Investigated drugs:

Guanfacine Hydrochloride Prolonged-release is a medication used in this trial to help manage symptoms of Attention-deficit/Hyperactivity Disorder (ADHD) in children and adolescents. It works by affecting certain parts of the brain to improve attention, focus, and impulse control. This medication is designed to release slowly over time, providing a steady effect throughout the day.

Atomoxetine is another medication being studied in this trial. It is used to treat ADHD by increasing the levels of certain chemicals in the brain that help with attention and impulse control. Unlike some other ADHD medications, atomoxetine is not a stimulant, which means it works differently and may be suitable for those who cannot tolerate stimulant medications.

Attention-deficit/hyperactivity disorder (ADHD) – ADHD is a neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. Inattention may manifest as wandering off task, lacking persistence, having difficulty sustaining focus, and being disorganized. Hyperactivity involves excessive movement, fidgeting, or an inability to stay still, while impulsivity refers to hasty actions that occur without forethought and have a high potential for harm. The symptoms typically appear before the age of 12 and can continue into adulthood. The disorder can lead to difficulties in academic, occupational, and social settings. The severity and specific symptoms can vary widely among individuals.

Trial ID:

2022-502630-71-00

Protocol code:

SPD503-401

NCT ID:

NCT04085172

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Guanfacine Hydrochloride and Atomoxetine Hydrochloride for Children and Adolescents with ADHD Aged 6 to 17 Years

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?